334 related articles for article (PubMed ID: 34426943)
1. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
4. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
7. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
9. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
10. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
11. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
[TBL] [Abstract][Full Text] [Related]
12. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
13. Future therapeutic options for patients with Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
[TBL] [Abstract][Full Text] [Related]
14. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
15. Waldenström macroglobulinemia.
Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
[TBL] [Abstract][Full Text] [Related]
16. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
17. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
Zanwar S; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
19. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
